利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.051 秒)

    Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
    24.
    发明申请
    Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators 审中-公开
    异噻唑啉-3（2H） - 二氧化硫作为肝X受体调节剂的非苯胺衍生物

    公开(公告)号：US20080319017A2

    公开(公告)日：2008-12-25

    申请号：US11813458

    申请日：2007-07-06

    申请人： Lanna Li ,  Marianne Swanson ,  Kay Brickmann

    发明人： Lanna Li ,  Marianne Swanson ,  Kay Brickmann

    IPC分类号： A61K31/4523 ,  C07D221/00 ,  A61K31/425 ,  A61P9/00 ,  C07D275/02

    CPC分类号： C07D275/03 ,  C07D417/14

    摘要： The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及式（I）的某些新化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和在 治疗和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。

    Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators
    25.
    发明申请
    Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators 审中-公开
    作为肝X受体调节剂的异噻唑-3（2H） - 硫酮-1,2-二氧化物的衍生物

    公开(公告)号：US20080125396A1

    公开(公告)日：2008-05-29

    申请号：US11813489

    申请日：2006-01-09

    申请人： Marianne Swanson ,  Kay Brickmann ,  Lanna Li

    发明人： Marianne Swanson ,  Kay Brickmann ,  Lanna Li

    IPC分类号： A61K31/695 ,  A61K31/425 ,  C07F5/02

    CPC分类号： C07D275/03

    摘要： The present invention relates to certain novel compounds of formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

    摘要翻译： 本发明涉及某些新的式（I）化合物，其用于制备这些化合物，用于调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）和治疗 和/或预防包括心血管疾病如动脉粥样硬化的临床病症; 炎性疾病，阿尔茨海默病，与胰岛素抵抗相关的脂质紊乱（血脂异常），2型糖尿病和代谢综合征的其他表现，其治疗用途的方法和含有它们的药物组合物。

    Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
    26.
    发明授权
    Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance 失效
    正离子取代的苯甲酸衍生物用于治疗胰岛素抵抗

    公开(公告)号：US07355069B2

    公开(公告)日：2008-04-08

    申请号：US10518007

    申请日：2003-06-17

    申请人： Lanna Li

    发明人： Lanna Li

    IPC分类号： C07C229/00 ,  C07C321/00 ,  C07C323/00 ,  C07C381/00 ,  A61K31/195

    CPC分类号： C07C235/34 ,  C07C323/62

    摘要： The present invention provides a compound of formula (I), wherein n is 0, 1 or 2 and R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents R1 may be the same or different; R2 represents a C2-8alkyl group which is optionally interrupted by oxygen; Y is absent or represents methylene; and X is O or S; and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them

    摘要翻译： 本发明提供式（I）化合物，其中n为0,1或2，R 1表示卤素，C 1-4烷基，任选地 被一个或多个氟，任选被一个或多个氟取代的C 1-4烷氧基取代，并且其中当n是2时，取代基R 1可以是 相同或不同; R 2表示任选被氧中断的C 2-8 C烷基; Y不存在或表示亚甲基; X为O或S; 及其药学上可接受的盐和前药，用于制备这些化合物的方法，用于治疗与胰岛素抵抗相关的临床病症，其治疗用途的方法和含有它们的药物组合物

    Benzoic acid derivatives as modulators of PPAR alpha and gamma
    30.
    发明授权
    Benzoic acid derivatives as modulators of PPAR alpha and gamma 失效

    公开(公告)号：US07521461B2

    公开(公告)日：2009-04-21

    申请号：US10518819

    申请日：2003-06-17

    申请人： Lanna Li

    发明人： Lanna Li

    IPC分类号： A61K31/47 ,  A61K31/44 ,  A61K31/426 ,  A61K31/4172 ,  A61K31/195 ,  C07C229/38

    CPC分类号： C07C59/68 ,  C07C233/78 ,  C07C235/34 ,  C07C275/30 ,  C07C309/66 ,  C07C311/13 ,  C07C323/62 ,  C07D213/38 ,  C07D217/06 ,  C07D233/54 ,  C07D307/68

    摘要： A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —(CH2)m-T-(CH2)n—U—(CH2)p— is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH2)2, O(CH2)3, NC(O)NR4(CH2)2, CH2S(O2)NR5(CH2)2, CH2N(R6)C(O)CH2, (CH2)2N(R6)C(O)(CH2)2, C(O)NR7CH2, C(O)NR7(CH2)2, and CH2N(R6)C(O)CH2O; V represents O, S, NR8 or a single bond; q represents 1, 2, or 3; W represents O, S, N(R9)C(O), NR10, or a single bond; R2 represents halo, a C1-4 alkyl group which is optionally substituted by one or more fluoro, a C1-4 alkoxy group which is optionally substituted by one or more fluoro, a C1-4 acyl group, aryl, an aryl C1-4 alkyl group, CN or NO2; r represents 0, 1, 2 or 3; R3 halo, a C1-4 alkyl group which is optionally substutited by one or more fluoro, a C1-4 alkoxy group which is optionally substituted by one or more fluoro, a C1-4 acyl group, aryl, an aryl C1-4 alkyl group, or CN; s represents 0, 1, 2 or 3; and R4, R5, R6, R7, R8, R9, and R10 independently represent H, a C1-10 alkyl group, aryl or an aryl C1-4 alkyl group or when m is O and T represents a group N(R6)C(O) or a group (R5)NS(O2) then R1 and R6 or R1 and R5 together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.